FDA Approves Alembic’s Generic Injection of Remodulin for PAH

FDA Approves Alembic’s Generic Injection of Remodulin for PAH

287320

FDA Approves Alembic’s Generic Injection of Remodulin for PAH

The U.S. Food and Drug Administration (FDA) has approved Alembic Pharmaceuticals’ injectable formulation of treprostinil, a generic version of Remodulin, to treat patients with pulmonary arterial hypertension (PAH), the company announced. Like the branded product, this generic version of United Therapeutics’ treprostinil will be available in multiple-dose vials containing four different concentrations  — 1.0, 2.5, 5.0, and 10 mg/mL — of the medication’s active ingredient. The FDA’s decision to approve this generic version of treprostinil followed the…

You must be logged in to read/download the full post.